Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.93
USD
|
+4.89%
|
|
+4.32%
|
+36.88%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,223
|
441.2
|
234.1
|
323.1
|
-
|
-
|
Enterprise Value (EV)
1 |
861.6
|
183.2
|
72.97
|
266.3
|
154.8
|
57.31
|
P/E ratio
|
-6.31
x
|
-2.71
x
|
-5.64
x
|
-2.49
x
|
-2.51
x
|
-4.13
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
60
x
|
1,894
x
|
1,094
x
|
1,292
x
|
1,292
x
|
8.72
x
|
EV / Revenue
|
42.3
x
|
786
x
|
341
x
|
1,065
x
|
619
x
|
1.55
x
|
EV / EBITDA
|
-6.35
x
|
-1.27
x
|
-0.58
x
|
-2.22
x
|
-1.12
x
|
-0.35
x
|
EV / FCF
|
-13.6
x
|
-1.74
x
|
-0.86
x
|
-2.64
x
|
-1.38
x
|
-0.4
x
|
FCF Yield
|
-7.36%
|
-57.4%
|
-116%
|
-37.9%
|
-72.6%
|
-251%
|
Price to Book
|
3.25
x
|
1.69
x
|
0.96
x
|
2.41
x
|
1.56
x
|
1.25
x
|
Nbr of stocks (in thousands)
|
160,298
|
165,875
|
166,010
|
167,413
|
-
|
-
|
Reference price
2 |
7.630
|
2.660
|
1.410
|
1.930
|
1.930
|
1.930
|
Announcement Date
|
3/30/22
|
3/24/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
20.38
|
0.233
|
0.214
|
0.25
|
0.25
|
37.06
|
EBITDA
1 |
-135.8
|
-144.6
|
-125.2
|
-119.8
|
-138.4
|
-164
|
EBIT
1 |
-135.8
|
-144.8
|
-125.5
|
-135.1
|
-153.8
|
-137.5
|
Operating Margin
|
-666.49%
|
-62,140.34%
|
-58,631.31%
|
-54,034.27%
|
-61,536.07%
|
-370.98%
|
Earnings before Tax (EBT)
1 |
-136.6
|
-135.2
|
-39.29
|
-135.5
|
-153.6
|
-124.1
|
Net income
1 |
-167.8
|
-152.4
|
-40.22
|
-132.9
|
-150.6
|
-120.1
|
Net margin
|
-823.56%
|
-65,401.29%
|
-18,796.26%
|
-53,164%
|
-60,259.27%
|
-324.1%
|
EPS
2 |
-1.210
|
-0.9800
|
-0.2500
|
-0.7750
|
-0.7700
|
-0.4675
|
Free Cash Flow
1 |
-63.42
|
-105.2
|
-84.38
|
-100.8
|
-112.4
|
-144.1
|
FCF margin
|
-311.24%
|
-45,167.38%
|
-39,428.5%
|
-40,320%
|
-44,961.07%
|
-388.8%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/22
|
3/24/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.266
|
0.23
|
-
|
0.17
|
0.024
|
0.038
|
0.037
|
0.172
|
0.087
|
0.018
|
-
|
-
|
-
|
0.3
|
EBITDA
1 |
-33.37
|
-45.15
|
-33.38
|
-35.34
|
-38.39
|
-37.51
|
-33.15
|
-31.78
|
-26.76
|
-33.46
|
-29.55
|
-29.7
|
-30.35
|
-30.25
|
EBIT
1 |
-33.36
|
-45.18
|
-33.44
|
-35.36
|
-38.42
|
-37.56
|
-33.21
|
-31.86
|
-26.83
|
-33.56
|
-30.84
|
-33.08
|
-33.13
|
-34.86
|
Operating Margin
|
-12,541.73%
|
-19,641.3%
|
-
|
-20,798.24%
|
-160,095.83%
|
-98,855.26%
|
-89,767.57%
|
-18,524.42%
|
-30,843.68%
|
-186,450%
|
-
|
-
|
-
|
-11,619.07%
|
Earnings before Tax (EBT)
1 |
-26.47
|
-48.58
|
-31.92
|
-30.81
|
-33.13
|
-39.32
|
-33.16
|
-31.66
|
43.85
|
-18.32
|
-30.7
|
-33.16
|
-33.41
|
-35.16
|
Net income
1 |
-31.16
|
-88.88
|
-36.87
|
-36.62
|
-33.89
|
-45.01
|
-33.14
|
-33.04
|
44.24
|
-18.29
|
-30
|
-32.38
|
-32.63
|
-34.31
|
Net margin
|
-11,713.53%
|
-38,642.17%
|
-
|
-21,540%
|
-141,195.83%
|
-118,450%
|
-89,554.05%
|
-19,210.47%
|
50,855.17%
|
-101,622.22%
|
-
|
-
|
-
|
-11,435.13%
|
EPS
2 |
-0.2100
|
-0.6200
|
-0.2400
|
-0.2400
|
-0.2200
|
-0.2800
|
-0.2100
|
-0.2100
|
0.2500
|
-0.1200
|
-0.1820
|
-0.1960
|
-0.1940
|
-0.1900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/15/21
|
3/30/22
|
5/16/22
|
8/15/22
|
11/10/22
|
3/24/23
|
5/11/23
|
8/10/23
|
11/14/23
|
3/28/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
362
|
258
|
161
|
56.8
|
168
|
266
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-63.4
|
-105
|
-84.4
|
-101
|
-112
|
-144
|
ROE (net income / shareholders' equity)
|
-71.8%
|
-47.8%
|
-16%
|
-59.1%
|
-58.1%
|
-45.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
2.350
|
1.570
|
1.460
|
0.8000
|
1.240
|
1.550
|
Cash Flow per Share
2 |
-0.4600
|
-0.6700
|
-0.5300
|
-0.3800
|
-0.3700
|
-0.4000
|
Capex
1 |
0.17
|
0.77
|
0.26
|
3.5
|
3.21
|
3.92
|
Capex / Sales
|
0.85%
|
331.76%
|
121.03%
|
1,400%
|
1,285.87%
|
10.58%
|
Announcement Date
|
3/30/22
|
3/24/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
1.93
USD Average target price
11.8
USD Spread / Average Target +511.40% Consensus |
1st Jan change
|
Capi.
|
---|
| +36.88% | 323M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|